{
  "nctId": "NCT06054269",
  "briefTitle": "Clinical Trial to Evaluate the Immunogenicity of an Adjuvanted Influenza Vaccine Among HCP",
  "officialTitle": "Randomized Controlled Trial, Double Blind, Phase III, to Evaluate the Immunogenicity of an Adjuvanted Influenza Vaccine Among Health Care Personnel (EDUCATE)",
  "protocolDocument": {
    "nctId": "NCT06054269",
    "filename": "Prot_SAP_000.pdf",
    "label": "Study Protocol and Statistical Analysis Plan",
    "date": "2023-04-14",
    "uploadDate": "2025-04-08T11:24",
    "size": 890999,
    "downloadUrl": "https://clinicaltrials.gov/api/v2/studies/NCT06054269/document/Prot_SAP_000.pdf",
    "hasProtocol": true,
    "hasSap": true,
    "hasIcf": false
  },
  "phase": [
    "PHASE3"
  ],
  "studyType": "INTERVENTIONAL",
  "allocation": "RANDOMIZED",
  "interventionModel": "PARALLEL",
  "masking": "QUADRUPLE",
  "enrollmentInfo": {
    "enrollmentCount": 192,
    "enrollmentType": "ACTUAL"
  },
  "timeline": {
    "startDate": "2022-11-04",
    "completionDate": "2026-03-31",
    "primaryCompletionDate": "2023-07-25",
    "firstSubmitDate": "2023-09-19",
    "firstPostDate": "2023-09-26"
  },
  "eligibilityCriteria": {
    "criteria": "Inclusion Criteria:\n\n* ≥18 years old;\n* Have participated in the healthcare personnel cohort study at Hospital Nacional Cayetano Heredia or Hospital Nacional Arzobispo Loayza during 2016-2021;\n* Work at the facility full-time (≥30 hours per week);\n* Have routine, direct, hands-on or face-to-face contact with patients (≤1 meter) as part of a typical work shift, including, but not limited to, physicians, nurses, respiratory therapists, physical therapists, unit clerks, radiograph technicians, medical assistants, and transporters;\n* Work at the facility for ≥1 year prior to enrollment and planning to continue working at the facility for one year after enrollment;\n* Willing to receive influenza vaccination (adjuvanted or standard dose);\n* Women of childbearing age must complete the following criteria to be eligible:\n\n  1. Have a negative urine pregnancy test performed by the study staff ≤24 hours preceding receipt of the vaccine;\n  2. Be willing to use a reliable form of contraception approved by the Investigator for ≤2 months after receiving the vaccine. If they are not currently using an approved contraceptive, study staff will provide access to contraceptives;\n  3. Must not be breastfeeding.\n\nExclusion Criteria:\n\n* Have received a vaccine against influenza during the 2022 influenza season (season of clinical trial);\n* Have a severe, life-threatening allergy to influenza vaccines, eggs, or influenza vaccine components;\n* Have a history of Guillain-Barre Syndrome or other autoimmune diseases;\n* Received blood or blood products within 3 months of enrollment;\n* Be pregnant, confirmed by rapid pregnancy test.",
    "healthyVolunteers": true,
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": [
      "ADULT",
      "OLDER_ADULT"
    ]
  },
  "endpoints": {
    "primary": [
      {
        "measure": "Hemagglutination Inhibition (HI) Geometric Mean Titers (GMT) Post-vaccination (Day 28) of Each Vaccine Reference Virus",
        "description": "The geometric mean of antibody titers after a single dose of FLUAD Quadrivalent (adjuvanted dose, AD) vs. FluQuadri (standard dose, SD) as measured by HI assay for egg-grown influenza A(H1N1)pdm09, A(H3N2), B/Yamagata, and B/Victoria vaccine reference viruses at approximately 28 days post-vaccination",
        "timeFrame": "28 days post-vaccination"
      },
      {
        "measure": "HI GMT Post-vaccination (6 Months) of Each Vaccine Reference Virus",
        "description": "The geometric mean of antibody titers after a single dose of AD vs SD vaccine as measured by HI assay for egg-grown influenza A(H1N1)pdm09, A(H3N2), B/Yamagata, and B/Victoria vaccine reference viruses at approximately 6 months post-vaccination",
        "timeFrame": "6 months post-vaccination"
      },
      {
        "measure": "Seroconversion Rate (SCR) to Each Vaccine Reference Virus Post-vaccination",
        "description": "The percent of participants with paired samples that achieved ≥4-fold rises comparing post- (approximately 28 days) versus pre-vaccination titers, and post-vaccination titers ≥40 for each vaccine reference virus (egg-grown influenza A(H1N1)pdm09, A(H3N2), B/Yamagata, and B/Victoria vaccine reference viruses) following a single dose of AD vs. SD vaccine.",
        "timeFrame": "28 days post-vaccination"
      },
      {
        "measure": "SCR to Each Vaccine Reference Virus Post-vaccination",
        "description": "The percent of participants with paired samples that achieved ≥4-fold rises comparing post- (approximately 6 months) versus pre-vaccination titers, and post-vaccination titers ≥40 for each vaccine reference virus (egg-grown influenza A(H1N1)pdm09, A(H3N2), B/Yamagata, and B/Victoria vaccine reference viruses) following a single dose of AD vs. SD vaccine.",
        "timeFrame": "6 months post-vaccination"
      },
      {
        "measure": "Seroprotection Rate (SPR) to Each Vaccine Reference Virus Post-vaccination",
        "description": "The percent of participants with post-vaccination titers ≥40 for each vaccine reference virus (egg-grown influenza A(H1N1)pdm09, A(H3N2), B/Yamagata, and B/Victoria vaccine reference viruses) following a single dose of AD vs. SD vaccine.",
        "timeFrame": "28 days post-vaccination"
      },
      {
        "measure": "SPR to Each Vaccine Reference Virus Post-vaccination",
        "description": "The percent of participants with post-vaccination titers ≥40 for each vaccine reference virus (egg-grown influenza A(H1N1)pdm09, A(H3N2), B/Yamagata, and B/Victoria vaccine reference viruses) following a single dose of AD vs. SD vaccine.",
        "timeFrame": "6 months post-vaccination"
      }
    ],
    "secondary": [],
    "other": []
  },
  "complexityMetrics": {
    "eligibilityCriteria": {
      "inclusionCount": 1,
      "exclusionCount": 1,
      "totalCount": 2
    },
    "endpoints": {
      "primaryCount": 6,
      "secondaryCount": 0,
      "otherCount": 0,
      "totalCount": 6
    },
    "studyDesign": {
      "phases": [
        "PHASE3"
      ],
      "isRandomized": true,
      "isMasked": true,
      "interventionModel": "PARALLEL"
    },
    "overallComplexityScore": 89,
    "complexityCategory": "Highly Complex"
  },
  "collectionDate": "2025-09-22T02:30:34.599Z",
  "dataSource": "ClinicalTrials.gov API v2 - Comprehensive Collection"
}